CHAPTER 1 INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2 RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1. Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3 MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4 MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Rising cell culture contamination
4.1.2. Increasing growth and government support for pharmaceutical and biotechnology industries
4.1.3. The strong trend of R&D investments in life sciences
4.1.4. Strict regulatory requirements
4.2. Market Restraints & Challenges
4.2.1. Shortage of skilled professionals
4.2.2. High degree of consolidation acts as an entry barrier for new entrants
4.3. Market Opportunities
4.3.1. Private exchanges providing great market potential
4.3.2. Increasing pharmaceutical outsourcing
CHAPTER 5 GLOBAL MYCOPLASMA TESTING MARKET – BY TECHNIQUE
5.1. Introduction
5.2. Enzymatic methods
5.3. Microbial culture techniques
5.4. DNA Staining
5.5. PCR
5.6. Elisa
5.7. Direct assays
5.8. Direct assays
CHAPTER 6 GLOBAL MYCOPLASMA TESTING MARKET – BY PRODUCT & SERVICE
6.1. Introduction
6.2. Instruments
6.3. Kits & reagents
6.3.1. PCR Assays
6.3.2. Nucleic acid detection kits
6.3.3. Elimination kits & reagents
6.3.4. Stains
6.3.5. Standards & controls
6.3.6. Other kits & reagents
6.4. Services
CHAPTER 7 GLOBAL MYCOPLASMA TESTING MARKET – BY APPLICATION
7.1. Introduction services
7.2. End-of-production cell testing
7.3. Cell line testing
7.4. Virus testing
7.5. Other applications
CHAPTER 8 GLOBAL MYCOPLASMA TESTING MARKET - BY END USER
8.1. Introduction
8.2. Academic research institutes
8.3. Cell banks
8.4. Pharmaceutical and biotechnology companies
8.5. Contract research organizations
8.6. Other end users
CHAPTER 9 GLOBAL MYCOPLASMA TESTING MARKET - BY GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.2.3. Mexico
9.2.4. Costa Rica
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Chile
9.3.4. Columbia
9.3.5. Others
9.4. Europe
9.4.1. U.K.
9.4.2. Germany
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Russia
9.4.7. Netherlands
9.4.8. Switzerland
9.4.9. Poland
9.4.10. Others
9.5. Asia Pacific
9.5.1. China
9.5.2. Japan
9.5.3. India
9.5.4. South Korea
9.5.5. Australia & New Zealand
9.5.6. Malaysia
9.5.7. Singapore
9.5.8. Others
9.6. Middle East & Africa
9.6.1. UAE
9.6.2. Saudi Arabia
9.6.3. Iran
9.6.4. Iraq
9.6.5. Qatar
9.6.6. South Africa
9.6.7. Algeria
9.6.8. Morocco
9.6.9. Nigeria
9.6.10. Egypt
9.6.11. Others
CHAPTER 10 GLOBAL MYCOPLASMA TESTING MARKET - COMPANY PROFILES
10.1. Thermo Fisher Scientific, Inc.
10.2. The Merck Group,
10.3. Lonza Group Ltd.
10.4. Promo Cell GmbH
10.5. American Type Culture Collection
10.6. Charles River Laboratories International, Inc.
10.7. Bionique Testing Laboratories, Inc.
10.8. Biological Industries Ltd.
10.9. InvivoGen,
10.10. WuXi AppTec Group
10.11. Norgen Biotek Corp.
10.12. SGS S.A.
10.13. F. Hoffmann-La Roche Ltd.
10.14. UnitedHealth Group Inc.
10.15. Allianz SE.
CHAPTER 11 GLOBAL MYCOPLASMA TESTING MARKET - COMPETITIVE LANDSCAPE
11.1. Market Share Analysis
11.2. Strategies adopted by top companies
11.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 12 MARKET INSIGHTS
12.1. Industry Experts Insights
12.2. Analysts Opinions
12.3. Investment Opportunities
CHAPTER 13 APPENDIX
13.1. List of Tables
13.2. List of Figures
